Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Determination of the Population Frequency of Monoallelic and Biallelic Predicted Pathogenic RPE65 Variants in a Normal Database. | Invest Ophthalmol Vis Sci | 2025 | 40879297 | PubTator, text mining | PubMed |
| Genetic Therapies for Retinitis Pigmentosa: Current Breakthroughs and Future Directions. | J Clin Med | 2025 | 40869487 | PubTator, text mining | PubMed |
| [Gene therapy methods for rare ophthalmological diseases in the light of distributional justice-An overview]. | Ophthalmologie | 2025 | 40864185 | PubTator, text mining | PubMed |
| Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium. | Transl Vis Sci Technol | 2025 | 40862658 | PubTator, text mining | PubMed |
| Therapeutic potential of allogeneic iPS cell-derived RPE transplantation for RPE65-LCA. | Am J Ophthalmol Case Rep | 2025 | 40852473 | PubTator, text mining | PubMed |
| Ocular Surveillance During Off-Label Oral Isotretinoin for Photoaging: A Review of Risks and Monitoring Recommendations. | J Cosmet Dermatol | 2025 | 40844045 | PubTator, text mining | PubMed |
| Restored phagocytic ability of RPE patches derived from gene-corrected retinitis pigmentosa-hiPSCs on a biodegradable scaffold via clinical-grade protocol: Implications for autologous therapy. | Genes Dis | 2025 | 40808876 | PubTator, text mining | PubMed |
| ECHS1: pathogenic mechanisms, experimental models, and emerging therapeutic strategies. | Orphanet J Rare Dis | 2025 | 40804397 | PubTator, text mining | PubMed |
| Visual cycle and LC3-associated phagocytosis in retina: regulatory mechanisms and therapeutic potential. | Biomed Pharmacother | 2025 | 40779887 | PubTator, text mining | PubMed |
| Short-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec. | Transl Vis Sci Technol | 2025 | 40757766 | PubTator, text mining | PubMed |
| A Practical Approach to Retinal Dystrophies. | Adv Exp Med Biol | 2025 | 40736857 | PubTator, text mining | PubMed |
| Endoplasmic reticulum-mitochondria coupling prompts ZBP1-mediated RPE cell PANoptosis in age-related macular degeneration. | Commun Biol | 2025 | 40731132 | PubTator, text mining | PubMed |
| In Situ Metabolic Rates of Alkane-Degrading Sulphate-Reducing Bacteria in Hydrocarbon Seep Sediments Revealed by Combining CARD-FISH, NanoSIMS, and Mathematical Modelling. | Environ Microbiol | 2025 | 40728192 | PubTator, text mining | PubMed |
| Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future Directions. | Genes (Basel) | 2025 | 40725503 | PubTator, text mining | PubMed |
| Exploring Concomitant Ophthalmic Comorbidities in Portuguese Patients with Inherited Retinal Diseases: A Comprehensive Clinical Study. | Genes (Basel) | 2025 | 40725401 | PubTator, text mining | PubMed |
| Regulation of RPE65 expression in human retinal pigment epithelium cells. | Sci Rep | 2025 | 40715346 | PubTator, text mining | PubMed |
| [Inherited retinal disorders: Current therapeutic options and future perspectives]. | Klin Monbl Augenheilkd | 2025 | 40701540 | PubTator, text mining | PubMed |
| Porcine Single-Eye Retinal Pigment Epithelium Cell Culture for Barrier and Polarity Studies. | Cells | 2025 | 40643526 | PubTator, text mining | PubMed |
| Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine. | Int J Mol Sci | 2025 | 40565081 | PubTator, text mining | PubMed |
| Molecular docking and molecular dynamics simulation studies of thiazole-coumarin and thiazole-triazole conjugates against Mpro and ACE2 receptor for SARS COV-2. | In Silico Pharmacol | 2025 | 40503560 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers?page=5